As a result, no anti-HER2 therapy was approved for use in urothelial carcinoma in the past decade, and the routine testing of HER2 was not recommended by clinical guidelines (ESMO) outside of clinical trials [12]. This evidence concerns the gene ERBB2 and urothelial carcinoma.